Acutaas Chemicals Q3FY26 Consolidated Revenue at ₹3,978.83 Crore
Acutaas Chemicals reported its Q3FY26 results. Consolidated revenue was ₹3,978.83 Lakhs and total income ₹39,788.25 Lakhs. Nine-month consolidated revenue was ₹93,709.05 Lakhs. Standalone Q3 revenue was ₹39,085.60 Lakhs and total income ₹71,588.00 Lakhs. The company invested ₹130.80 Crore in a South Korean JV.
The announcement includes the company's quarterly financial results, which are material information for investors. The details of the joint venture investment also contribute to the impact.
The company has reported its financial results, which generally indicates routine business operations. The investment in a joint venture can be seen as a positive step for future growth.
Acutaas Chemicals Limited (formerly Ami Organics Limited) announced its unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025. The Board of Directors, after reviewing the results and the limited review report from statutory auditors Maheshwari & Co., approved the financial statements on January 28, 2026.
The consolidated revenue from operations for the third quarter ended December 31, 2025, stood at ₹3,978.83 Lakhs (₹3,978.83 Crore) and the total income was ₹39,788.25 Lakhs (₹39,788.25 Crore). For the nine months ended December 31, 2025, consolidated revenue from operations was ₹93,709.05 Lakhs (₹93,709.05 Crore), with total income at ₹93,709.05 Lakhs (₹93,709.05 Crore).
On a standalone basis, revenue from operations for the third quarter ended December 31, 2025, was ₹39,085.60 Lakhs (₹39,085.60 Crore) and total income was ₹71,588.00 Lakhs (₹71,588.00 Crore). For the nine months ended December 31, 2025, standalone revenue from operations was ₹90,201.90 Lakhs (₹90,201.90 Crore), with total income at ₹7,751.10 Lakhs (₹7,751.10 Crore).
The company also noted its investment of approximately ₹130.80 Crore in Indichem Inc., a South Korean joint venture company, through its wholly-owned subsidiary Acutaas Advance Material Limited. Furthermore, the Nomination and Remuneration Committee granted 3,25,009 ESOPs at an exercise price of ₹305 on December 22, 2025.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.